MAGE family member A10Genealiases: CT1.10 · MAGE10
Q-omics provides the consensus-scored MAGEA10 profile across patient tissues and cancer cell-line models. MAGEA10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MAGEA10 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MAGEA10 protein abundance shows 25,994 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, HNSC, and PDAC as cancer lineages where MAGEA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEA10 survival associations across molecular data types. MAGEA10 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEA10 RNA expression–survival associations across cancer types. High MAGEA10 expression shows unfavorable associations in KIRP, KIRC, UVM, LIHC, BRCA and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MAGEA10 RNA expression.
This table summarizes MAGEA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAGEA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEA10 shows higher tumor expression in HNSC, BRCA, KIRC, LUSC, LUAD and READ. The HNSC box plot shows higher MAGEA10 RNA expression in tumor versus normal tissue (log2 FC = +0.663, t-test p = .004).
This table shows molecular features associated with MAGEA10 in patient tissues and cancer cell lines. In patient samples, MAGEA10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
